Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 125 of 2529 entries
View as:

Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder

Phase: N/A Priority: Normal
NCT ID: NCT00107939 Org: User:
Start: 11/30/04 End: 04/30/07 Due: 04/30/08

Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Rituximab-refractory Follicular Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT01275209 Org: User:
Start: 02/28/11 End: 05/31/12 Due: 05/31/13

Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01820325 Org: User:
Start: 09/09/13 End: 06/18/14 Due: 06/18/15

Pharmacokinetics, Safety and Tolerability of AGO178C in Subjects With Renal Deficiencies Compared With Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01459250 Org: User:
Start: 03/31/11 End: - Due: -

EPO906 Therapy in Patients With Advanced Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00035087 Org: User:
Start: 05/31/02 End: 03/31/03 Due: 03/31/04

Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A

Phase: N/A Priority: Normal
NCT ID: NCT03447769 Org: User:
Start: 03/16/18 End: 02/07/23 Due: 02/07/24

A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT02108964 Org: User:
Start: 06/06/14 End: 08/15/23 Due: 08/15/24

Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment

Phase: N/A Priority: Normal
NCT ID: NCT05631795 Org: User:
Start: 08/09/22 End: 11/03/25 Due: 11/03/26

A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM)

Phase: N/A Priority: Normal
NCT ID: NCT02720510 Org: User:
Start: 06/14/16 End: 05/22/17 Due: 05/22/18

A Study to Evaluate Clear Skin Effect on Quality of Life in Patients With Plaque Psoriasis.

Phase: N/A Priority: Normal
NCT ID: NCT02752776 Org: User:
Start: 03/17/16 End: 03/28/18 Due: 03/28/19

Pharmacokinetics and Pharmacodynamics Study of SEG101 (Crizanlizumab) in Sickle Cell Disease (SCD) Patients With Vaso- Occlusive Crisis (VOC)

Phase: N/A Priority: Normal
NCT ID: NCT03264989 Org: User:
Start: 12/19/17 End: 06/26/23 Due: 06/26/24

Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis

Phase: N/A Priority: Normal
NCT ID: NCT01423110 Org: User:
Start: 08/31/11 End: 05/31/12 Due: 05/31/13

Risk Perception in Multiple Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT05528666 Org: User:
Start: 09/09/21 End: 09/17/21 Due: 09/17/22

Extension to CQTI571A2102 to Evaluate Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)

Phase: N/A Priority: Normal
NCT ID: NCT01392495 Org: User:
Start: 06/30/11 End: 03/31/14 Due: 03/31/15

Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD)

Phase: N/A Priority: Normal
NCT ID: NCT05269966 Org: User:
Start: 03/09/22 End: 08/29/23 Due: 08/29/24

A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED)

Phase: N/A Priority: Normal
NCT ID: NCT04737330 Org: User:
Start: 11/29/21 End: 05/16/23 Due: 05/16/24

Comparison of CNI-based Regimen Versus CNI-free Regimen in Kidney Transplant Recipients.

Phase: N/A Priority: Normal
NCT ID: NCT00332839 Org: User:
Start: 11/30/05 End: 03/31/13 Due: 03/31/14

Swiss studY for the Treatment of COPD Patients With the Free combiNation of indacatERol and GlYcopyrroniumbromide.

Phase: N/A Priority: Normal
NCT ID: NCT01699685 Org: User:
Start: 11/30/12 End: 06/30/14 Due: 06/30/15

A Norwegian Observational Trial Evaluating the Treatment of Advanced Renal Cell Cancer Patients Under Treatment of Afinitor

Phase: N/A Priority: Normal
NCT ID: NCT01390519 Org: User:
Start: 06/30/11 End: 12/31/15 Due: 12/31/16

Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy

Phase: N/A Priority: Normal
NCT ID: NCT04278417 Org: User:
Start: 11/19/20 End: 08/19/24 Due: 08/19/25

Study of PIK3CA Mutations and Effectiveness and Tolerability Outcomes of Alpelisib in Real-world

Phase: N/A Priority: Normal
NCT ID: NCT05022342 Org: User:
Start: 10/27/21 End: 09/30/25 Due: 09/30/26

Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02393625 Org: User:
Start: 05/27/15 End: 04/10/25 Due: 04/10/26

Study of Pharmacodynamic Effects of VAY736 in Patients With Primary Sjögren's Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT02495129 Org: User:
Start: 12/31/15 End: 09/30/17 Due: 09/30/18

Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis

Phase: N/A Priority: Normal
NCT ID: NCT00035997 Org: User:
Start: 04/30/02 End: 01/31/04 Due: 01/31/05

Dose-ranging Safety and Tolerability Study in Subjects ≥60 Years of Age

Phase: N/A Priority: Normal
NCT ID: NCT02576639 Org: User:
Start: 08/10/15 End: 03/11/16 Due: 03/11/17